Operating
D&A
Neurocrine Biosciences D&A increased by 12.5% to $7.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.1%, from $6.60M to $7.20M. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 24.3% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
Higher levels indicate significant capital investment in infrastructure or acquisitions, while lower levels may suggest aging assets or limited capital expenditure.
Detailed definition
This represents the non-cash expense allocated to the cost of tangible and intangible assets over their useful lives. Be...
Peer comparison
High in capital-intensive industries like manufacturing and healthcare devices; lower in service-based sectors.
Metric ID:
depreciation_and_amortization_cfHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.60M | $2.80M | $3.00M | $3.30M | $3.90M | $4.00M | $3.90M | $4.10M | $4.20M | $4.60M | $4.90M | $5.30M | $6.40M | $5.60M | $6.20M | $6.60M | $6.30M | $6.70M | $6.40M | $7.20M |
| QoQ Change | — | +7.7% | +7.1% | +10.0% | +18.2% | +2.6% | -2.5% | +5.1% | +2.4% | +9.5% | +6.5% | +8.2% | +20.8% | -12.5% | +10.7% | +6.5% | -4.5% | +6.3% | -4.5% | +12.5% |
| YoY Change | — | — | — | — | +50.0% | +42.9% | +30.0% | +24.2% | +7.7% | +15.0% | +25.6% | +29.3% | +52.4% | +21.7% | +26.5% | +24.5% | -1.6% | +19.6% | +3.2% | +9.1% |
Range$2.60M – $7.20M
CAGR+23.9%
Avg YoY Growth+23.8%
Median YoY Growth+24.4%
D&A at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's d&a?
- Neurocrine Biosciences (NBIX) reported d&a of $7.20M in Q1 2026.
- How has Neurocrine Biosciences's d&a changed year-over-year?
- Neurocrine Biosciences's d&a increased by 9.1% year-over-year, from $6.60M to $7.20M.
- What is the long-term trend for Neurocrine Biosciences's d&a?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's d&a has grown at a 24.3% compound annual growth rate (CAGR), from $10.90M to $26.00M.
- What does d&a mean?
- The non-cash accounting expense for the wear and tear or expiration of assets.